Q1 2026 Omeros Corp Earnings Call Transcript
Key Points
- Omeros Corp (OMER) successfully launched YARTEMLEA, the first and only approved treatment for TA-TMA, generating $11.1 million in gross revenues and $9.9 million in net revenues in the first quarter.
- The company received $240 million in upfront cash from a transaction with Novo Nordisk, with potential for an additional $100 million in near-term milestone payments.
- YARTEMLEA has been adopted by 30 unique accounts, with significant uptake in major transplant centers, indicating strong early demand.
- The FDA approval of YARTEMLEA and the assignment of a Permanent Healthcare Common Procedure Coding System (J-code) by CMS are expected to simplify billing and reimbursement, enhancing patient access.
- Omeros Corp (OMER) is expanding its MASP-2 program and exploring additional indications for YARTEMLEA, including ARDS and sickle cell disease, which could broaden its market potential.
- Despite the positive launch of YARTEMLEA, Omeros Corp (OMER) reported a non-GAAP adjusted net loss of $17.1 million for the first quarter.
- The company faces volatility in its financial results due to non-cash mark-to-market adjustments on embedded derivatives, which can significantly impact reported earnings.
- Omeros Corp (OMER) is still in the early stages of YARTEMLEA's launch, with no revenue guidance provided, making future financial performance uncertain.
- The company has significant debt obligations, with $70.8 million outstanding on its 2029 convertible notes, which could impact future financial flexibility.
- There is competition in the TA-TMA treatment space, with AstraZeneca conducting a Phase 3 study for a similar indication, which could affect YARTEMLEA's market position.
Good afternoon and welcome to today's earnings call for Omeros Corporation. (Operator Instructions)
Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website.
I'll now turn the call over to Jennifer Williams, Investor Relations for Omeros. Please go ahead.
Thank you, and good afternoon, everyone. Before we begin, please note that today's discussion will include forward-looking statements. These statements reflect management's current expectations and beliefs as of today and are subject to risks and uncertainties that could cause actual results to differ materially.
For a detailed discussion of these risks and uncertainties, please refer to the special note regarding forward-looking statements and the risk factors sections in our quarterly report on Form 10-Q filed today with the SEC, as well as our most recent annual report on Form 10-K.
Today's call will include a discussion of certain non-GAAP
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
